Verrica Pharmaceuticals Inc.(VRCA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Verrica Pharmaceuticals Inc. (VRCA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VRCA at 32.7/100 on a 32-signal composite quality model, placing it at rank #2,418 of 2,962 stocks — the bottom half of the AI-ranked universe. VRCA scores in the top quartile across revenue growth (94.7). Areas of concern include balance sheet strength (1.5) and revenue scale (5.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Verrica Pharmaceuticals Inc. reports quarterly revenue of $5.9M, net income of $-13.2M. Top institutional holders of VRCA by reported 13-F value include Caligan Partners, CANNELL CAPITAL, Affinity Asset Advisors, based on the most recent SEC filings. VRCA trades on the Nasdaq exchange and files with the SEC under CIK 1660334. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VRCA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Verrica Pharmaceuticals Inc. directly from SEC EDGAR.